| Old Articles: <Older 2841-2850 Newer> |
 |
The Motley Fool April 20, 2006 John Bluis |
Investors Jump Ship at Genzyme Clearly, Genzyme continues to invest in its business for the long term. That's the type of approach that can create a steady stream of market-beating returns for investors if they're willing to trust management.  |
The Motley Fool April 19, 2006 Brian Gorman |
Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge.  |
BusinessWeek April 24, 2006 Arlene Weintraub |
Eyes Wide Open Cephalon's careful marketing of its narcolepsy drug could serve as a manual for turning new ideas into hit products.  |
BusinessWeek April 24, 2006 Arlene Weintraub |
A Cephalon Vet Takes On Insomnia Jack Lief helped create Provigil, the elixir of wakefulness. But his startup is committed to helping people sleep.  |
The Motley Fool April 17, 2006 Brian Gorman |
Novartis Presses on Biogenerics The company wins a court case that could accelerate U.S. regulations for biogenerics. Recent developments suggest Novartis' strategy may be close to paying off. Investors, take note.  |
Bio-IT World April 2006 John Russell |
Pfizer's Pursuit of Technology Can this $50-billion-plus, 115,000-employee behemoth succeed where other pharma giants have failed and successfully institutionalize the effort to find and develop critical new technology? Should it even try?  |
Bio-IT World April 2006 Laura Huckabee-Jennings |
Southern Emergence Why Huntsville, Alabama, will be the next biotech hotbed.  |
Bio-IT World April 2006 Samara McCarthy |
Ireland's Biotech Boom How the Emerald Isle has made its name in the life sciences.  |
Bio-IT World April 2006 Kevin Davies |
Microsoft Forges BioIT Alliance The software giant's fledgling alliance aims to bring together companies from a cross-section of the industry -- from biotech and Big Pharma to equipment manufacturers and software developers -- to collaborate on technology that will speed drug discovery.  |
Bio-IT World April 2006 Kevin Davies |
Putting the IT in Clinical Trials A new report says that the clinical trials process must be reinvented to reverse the output decline of the pharmaceutical industry and meet the needs of its patients. That reinvention will be shaped by major advances in information technology.  |
| <Older 2841-2850 Newer> Return to current articles. |